Skin patch vaccine neutralizes COVID-19 in mice

A vaccine against COVID-19 (SARS-CoV-2) administered through a skin patch has succeeded in neutralizing the virus in mice, inducing higher levels of antibodies than alternatives.

The vaccine candidate is Hexapro, from University of Texas, and has been administered by means of a patch developed by the University of Queensland; the prototype provided protection against covid-19 disease with a painless “click” performed with a pocket applicator.

David Muller, from the Queensland College of Chemistry and Molecular Biosciences, explains that the vaccine patch produced strong immune responses that were effective when mice were exposed to the SARS-CoV-2, the virus that causes COVID-19.

“When the Hexapro vaccine is administered through the high intensity microarray patch, instead of a needle, it produces better and faster immune responses”, summarizes the researcher, who assures that “It also neutralizes multiple variants, including those originating in the UK and South Africa”.

“In addition, it is much easier to use than a needle: just click on the applicator on the skin and 5,000 microscopic projections introduce the vaccine into the skin almost imperceptibly”continues the expert.

Hexapro could help “dramatically” the global vaccine implementation effort, especially for millions of vulnerable people in low- and middle-income countries, according to a statement from Queensland.

The authors further note that the patches can facilitate the administration of vaccines, since the process does not require trained healthcare professionals, and the technology does not need to be stored at ultra-low temperatures either.

According to the scientists, who publish their developments in the journal Science Advances, the prototype vaccine, when dry coated in a patch, is stable for at least 30 days at 25 degrees Celsius and one week at 40 degrees, “So you don’t need the cold chain requirements of some of the current options”.

Muller points out that the Queensland team, together with Vaxxas – the company that markets the patch – expects “Bring technology to the world” and is looking for funding opportunities to accelerate the start of clinical trials as much as possible.